Carlile D J, Zomorodi K, Houston J B
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK.
Drug Metab Dispos. 1997 Aug;25(8):903-11.
Microsomal protein recovery and hepatocellularity have been determined and investigated as scaling factors for interrelating clearance by hepatic microsomes, freshly isolated hepatocytes and whole liver from untreated (UT) rats and rats treated with either the cytochrome P450 inducer phenobarbital (PB) or dexamethasone (DEX). Hepatocellularity in UT rats (1.1 x 10(8) hepatocytes/g liver) was not significantly different after either PB or DEX induction (1.1 and 1.3 x 10(8) hepatocytes/g liver, respectively). However the microsomal protein recovery index, which provides a scaling factor that is inversely related to the efficiency of the microsomal preparation procedure, was 47 mg/g liver in both PB and DEX microsomes and differs from UT rats (60 mg/g liver). These contrasting findings are consistent with the interlaboratory trends in the literature, indicating that, although hepatocellularity estimates are in good accord, microsomal recovery can vary 2-fold; this has implications for scaling. The oxidation of diazepam to its three primary metabolites was measured in PB and DEX microsomes and hepatocytes and the scaling factors were applied to these data and previously reported UT data. Marked changes in kinetics occur on induction resulting in a shift in the major pathway. In particular, 3-hydroxylation is induced over 20-fold by DEX. Diazepam CL(int) was determined in vivo after administration of a bolus dose into the hepatic portal vein of UT, PB, and DEX rats; values of 127, 191, and 323 ml/min/SRW (where SRW is a standard rat weight of 250 g), respectively, were obtained. Using these scaling factors, the hepatocyte predictions of CL(int) were excellent (99, 144, and 297 ml/min/SRW for UT, PB, and DEX, respectively), whereas only the DEX prediction (248 ml/min/SRW) was accurate for the microsomal system, with a substantial underprediction for UT and PB (46 and 68 ml/min/SRW, respectively). Evidence is presented for product inhibition, resulting from accumulation of primary metabolites within the microsomal preparation, as the mechanism responsible for this underprediction. These results illustrate that the scaling factor approach is applicable to induced livers in which both cytochrome P450 complement and zonal distribution are altered. These data, together with our previous studies, demonstrate that CL(int) in cells (2.4-297 ml/min/SRW), microsomes (2.7-248 ml/min/SRW), and in vivo (1.5-323 ml/min/SRW) are related in a linear fashion and hence inherently both in vitro systems are of equal value in predicting in vivo CL(int).
已测定并研究了微粒体蛋白回收率和肝细胞数量,作为将肝微粒体、新鲜分离的肝细胞以及未处理(UT)大鼠和用细胞色素P450诱导剂苯巴比妥(PB)或地塞米松(DEX)处理的大鼠的全肝清除率相互关联的标度因子。UT大鼠的肝细胞数量(1.1×10⁸个肝细胞/g肝脏)在PB或DEX诱导后无显著差异(分别为1.1和1.3×10⁸个肝细胞/g肝脏)。然而,微粒体蛋白回收率指数,它提供了一个与微粒体制备程序效率成反比的标度因子,在PB和DEX微粒体中均为47mg/g肝脏,与UT大鼠(60mg/g肝脏)不同。这些对比结果与文献中的实验室间趋势一致,表明尽管肝细胞数量估计结果相符,但微粒体回收率可相差2倍;这对标度有影响。在PB和DEX微粒体及肝细胞中测定了地西泮氧化为其三种主要代谢物的情况,并将标度因子应用于这些数据以及先前报道的UT数据。诱导后动力学发生显著变化,导致主要途径发生转变。特别是,DEX诱导3-羟基化超过20倍。在UT、PB和DEX大鼠的肝门静脉推注给药后,在体内测定了地西泮的内在清除率(CL(int));分别获得了127、191和323ml/min/SRW(其中SRW是250g的标准大鼠体重)的值。使用这些标度因子,肝细胞对CL(int)的预测非常出色(UT、PB和DEX分别为99、144和297ml/min/SRW),而对于微粒体系统,只有DEX的预测(248ml/min/SRW)准确,UT和PB的预测值大幅偏低(分别为46和68ml/min/SRW)。有证据表明,微粒体制备中主要代谢物的积累导致产物抑制,是这种预测偏低的原因。这些结果表明,标度因子方法适用于细胞色素P450组成和区域分布均发生改变的诱导肝脏。这些数据,连同我们之前的研究,表明细胞(2.4 - 297ml/min/SRW)、微粒体(2.7 - 248ml/min/SRW)和体内(1.5 - 323ml/min/SRW)的CL(int)呈线性相关,因此从本质上讲,两种体外系统在预测体内CL(int)方面具有同等价值。